These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 17559147

  • 1. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 2. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
    Breast Cancer Res Treat; 2004 Jul 01; 86(1):9-18. PubMed ID: 15218357
    [Abstract] [Full Text] [Related]

  • 3. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C.
    Anticancer Res; 2006 Jul 01; 26(2B):1479-87. PubMed ID: 16619561
    [Abstract] [Full Text] [Related]

  • 4. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.
    Cancer; 2006 Nov 15; 107(10):2337-45. PubMed ID: 17048231
    [Abstract] [Full Text] [Related]

  • 5. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H.
    Oncol Rep; 2004 Jun 15; 11(6):1331-6. PubMed ID: 15138574
    [Abstract] [Full Text] [Related]

  • 6. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M.
    J Clin Oncol; 2009 Nov 20; 27(33):5552-8. PubMed ID: 19858400
    [Abstract] [Full Text] [Related]

  • 7. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, Samonigg H, Bauernhofer T.
    Am J Clin Pathol; 2007 Oct 20; 128(4):630-7. PubMed ID: 17875515
    [Abstract] [Full Text] [Related]

  • 8. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, Glück S.
    Bone Marrow Transplant; 1999 Aug 20; 24(4):377-84. PubMed ID: 10467326
    [Abstract] [Full Text] [Related]

  • 9. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC, Cancer and Leukemia Group B.
    Clin Cancer Res; 2001 Sep 20; 7(9):2703-11. PubMed ID: 11555582
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L, Viale G.
    Anticancer Res; 2004 Sep 20; 24(2C):1261-6. PubMed ID: 15154657
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A.
    Neoplasma; 2008 Jun 01; 55(2):113-21. PubMed ID: 18237248
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA.
    Cancer; 2005 Aug 15; 104(4):676-81. PubMed ID: 15981280
    [Abstract] [Full Text] [Related]

  • 17. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M.
    Cancer; 2007 Feb 01; 109(3):496-501. PubMed ID: 17149760
    [Abstract] [Full Text] [Related]

  • 18. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondón G, Champlin RE, Sahin AA, Ueno NT.
    Clin Cancer Res; 2001 Dec 01; 7(12):4008-12. PubMed ID: 11751494
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Tzaida O, Gogas H, Dafni U, Kyroudi A, Papaspyrou I, Kyriakou V, Malamou-Mitsi V, Alamani M, Skopa C, Kostopoulos I, Kastritis E, Pectasides D, Briasoulis E, Kalofonos HP, Aravantinos G, Fountzilas G, Arapantoni-Dadioti P.
    Oncology; 2007 Dec 01; 72(5-6):388-96. PubMed ID: 18187961
    [Abstract] [Full Text] [Related]

  • 20. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.
    Cancer; 2005 Jul 15; 104(2):257-63. PubMed ID: 15952182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.